Our team has initiated a phase I clinical study to evaluate the safety and efficacy of RJMty19, an allogeneic CD19‐CAR‐DNT cell product, in the treatment of relapsed and refractory B‐NHL (NCT06314828) and systemic lupus erythematosus (NCT06340490). Here, CD19 is linked to systemic lupus erythematosus.